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KObjectives: To evaluate the preferences of health care professional
groups and patient groups with respect to efficacy, adverse events, and
administration method for targeted agents of metastatic renal cell
carcinoma. Methods: A total of 485 respondents including cancer pa-
ients and health care professionals (medical oncologists, nurses, and
harmacists) were surveyed by using a discrete choice experiment in
outh Korea. Through a literature review and expert consultation, six
ttributes—progression-free survival, four adverse events (bone mar-
ow suppression, hand-foot skin reaction, gastrointestinal perforation,
nd bleeding), and administration—were selected. This study em-
loyed the conditional logit regression model. Results: The six attri-
utes are statistically significant for the patient group and health care
rofessional group. The two groups, however, present differences in
rogression-free survival, hand-foot skin reaction, gastrointestinal
erforation, and administration. The relative importance of adverse
vents is greater for the patient group, while that of efficacy and ad-
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http://dx.doi.org/10.1016/j.jval.2012.05.008inistration is greater for the health professional group. For doctors,
he relative importance of efficacy is as high as 31%, compared with 7%
or the patient group. If progression-free survival is prolonged by 1
onth, the acceptable level of bonemarrow suppression is 1.3% for the
atient group and 9.6% for doctors and that of hand-foot skin reaction
s 1.0% and 11.8%, respectively, for the patient group and doctors.
onclusions: This study demonstrates substantial differences in the
reference for a targeted drug between the patient group and the
ealth care professional group. Doctors prefer effective and orally ad-
inistered drugs while patients show more reluctant attitudes about
dverse events than do health care professionals.
eywords: discrete choice experiment, preference, relative importance,
renal cell carcinoma, trade-off.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Metastatic renal cell carcinoma (mRCC) is resistant to frequently
used cytotoxic chemotherapy or radiotherapy [1], and the efficacy of
immune therapy for mRCC has also been limited [2]. Therefore, pa-
tients suffering from mRCC did not have many choices regarding
treatmentprior to thedevelopmentof targeted therapy.Asa result of
recent studies on themolecular mechanism of renal cell carcinoma,
targeted agents for suppressing the angiogenesis of tumor cells have
been developed [3] and proven to prolong the progression-free sur-
ival (PFS) and the overall survival (OS) of the patient.
There are several targeted agents in the treatment for mRCC,
ut they differ from each other in terms of efficacy, adverse event
rofiles, and administration [4]. For instance, sunitinib is different
from bevacizumab even though they are both targeted agents that
can be regarded as primary standard treatments for mRCC.
Sunitinib is more efficacious and is an orally administered drug
but has numerous more adverse events while bevacizumab has
fewer adverse events but is less effective and is an intravenously
administered drug [4–6].
* Address correspondence to: Eui-Kyung Lee, Pharmaceutical Polic
sity, 300 Cheonchoen-dong, Jangan-Gu, Suwon, Gyeongi-Do 440-7
E-mail: ekyung@skku.edu.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.Generally, preference for a drug depends on not only the effi-
acy of the drug but also various other attributes such as adverse
vents and the administration method. It can thus be anticipated
hat the preferences of not only health care professionals but also
atients would have an impact on the successful treatment of
isease. In the treatment of relatively severe diseases such as can-
er, patients usually passively follow the treatment suggested and
etermined by the medical staff because of information asymme-
ry relating to their diseases and drugs [7,8]. If, however, the effi-
acy does not satisfy their expectations or if adverse events that
re unexpected or serious or reduce quality of life occur, their
ompliance and, consequently, the treatment outcome would be
egatively affected [9,10]. Good communication between a physi-
ian and a patient can lead to the patient’s active participation in
he treatment decision, which is related to improved outcomes
11–13]. The preferences ofmedical staff and patients and the gaps
etween these two groups should hence be carefully examined.
The discrete choice experiment (DCE) evaluates a product’s
alue by considering several of its representative attributes. In the
eld of health care research, the DCE is used in examining the
utcomes Research, School of Pharmacy, Sungkyunkwan Univer-
uth Korea.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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934 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 3 3 – 9 3 9preferences for drugs or treatments as well as the willingness to
pay [14–19]. This study, through a DCE survey, aimed to elicit the
references of medical staff and patients/patients’ family mem-
ers for recently developed targeted agents used in mRCC and to
dentify the significantly important factors influencing drug pref-
rence.
Methods
DCE methodology
A DCE assumes that the utility of a certain product is determined
by several product attributes and their levels [20,21]. In a DCE,
hypothetical scenario sets with differing levels of attributes are
presented to respondents; each respondent combines the infor-
mation and chooses the most preferable among the alternatives.
The value of the product is estimated from the combination of
attributes and levels selected [22]. The attributes should have sig-
ificant impacts on drug selection; the levels should be realisti-
ally achievable to the extent that the respondents can carefully
onsider them in the selection [20].
The relative importance of each attribute for preferences and
he trade-offs between attributes can be estimated from the re-
ults chosen by respondents by considering different attribute lev-
ls [15,16,18].
Attributes and attribute levels
Attributes and their levels were identified by a literature review on
sunitinib and bevacizumab and were then finalized after expert
consultation [23–26]. In addition to these drugs, there are several
other targeted agents used for mRCC that have various adverse
events. Because of the DCEmethodology, however, we focused on
these two representative drugs, which are the most common tar-
geted agents as primary standard treatments formRCC, and chose
a limited number of attributes. On the basis of a comprehensive
literature review and expert opinions, we selected two major and
typical adverse events for each drug that are extremely severe or
have a significant impact on the quality of life for patients and
hence should be carefully considered in drug use.
As an efficacy attribute, PFSwas selected. For ethical reasons in
clinical trials, additional treatment is usually permitted after pro-
gression of disease and thus OS cannot be seen as a pure efficacy
attribute of the drug while PFS appears to be more specific to an
individual drug. Selected as adverse events were hand-foot skin
reaction (HFSR), bone marrow suppression (BMS), gastrointestinal
(GI) perforation, and bleeding. PFS and the four adverse events
were defined according to three levels by extension to a hypothet-
ical range based on clinical literature. Sunitinib is orally adminis-
tered once a day. Bevacizumab is intravenously injected at the
hospital once every 2 weeks but must be administered with inter-
feron- for mRCC, and thus three-times-per-week subcutaneous
elf-injection at homewas included in the category of administra-
ion method (Table 1).
Table 1 – Attributes and levels for targeted drugs.
Attributes of first-line therapy
Progression-free survival: PFS (mo) 10
Bone marrow suppression: BMS (%) 1
Hand-foot skin reaction: HFSR (%) 0
Gastrointestinal (GI) perforation (%) 0
Bleeding (%) 0
Administration (0  oral, 1  injection) 0DCE scenario
The levels of six attributes were 3, 3, 3, 3, 3, and 2, and therefore
486 hypothetical profiles were available (i.e., 35*2). We selected
similar structures for the attributes and levels as presented in our
study “A Library of Orthogonal Arrays” (N.J.A.Sloan, http://
www2.research.att.com/njas/oadir/) to form 18 arrays and gen-
erated scenario sets by the fold-over method. In this case, two
treatments always have different levels within the scenario set;
the generated scenario sets meet orthogonality and minimum
overlapping and achieve equal balancewhere the same number of
levels should be included (Fig. 1).
Asking the patients and patients’ familymembers to answer all
the 18 choice sets may disturb rational judgment, and conse-
quently theywere randomly divided to create two versions. A total
of 10 questionswere asked,with one dominant choice set added to
the last part of the questionnaire for an irrationality check. A pilot
test was carried out with 20 persons to check for any problems.
After examining terminology and other factors, the final question-
naires were completed. Prior to answering DCE questions, respon-
dents were asked to rank four adverse events used in the survey to
identify their perception on severity.
In the DCE questionnaire, the drug name was not stated to
avoid any possible selection bias and hence respondents chose
their preference between drug A and drug B in the hypothetical
scenario set. In the survey questionnaire, brief explanations of the
terminologies used in the questionnaire were provided with sim-
ple terms to aid in the respondents’ understanding.
Data collection
The survey was carried out separately for the patient group and
the health care professional group. The former group included
cancer patients and their family members, while the latter group
included doctors (medical oncologists), nurses (oncology nurses
and general nurses), and pharmacists in South Korea. The survey
Levels Coefficients in
regression analysis
11 13 1
9 18 2
5 10 3
1 2 4
2 4 5
BgurDAgurD
Progression-free survival 10 months 11 months 
Bone marrow suppression 
(neutropenia/thrombocytopenia) 9%1%
5%% 0noitcaernikstoof-dnaH
2%1%noitarofreplanitsetniortsaG
% 04%gnideelB
Administration  Orally once a day (at home) 
Intravenous injection once 
every 2 weeks (at hospital) 
and subcutaneous injection 
three times a week (at home) 
Which would you choose 
between  
Drug A and Drug B? 
Fig. 1 – Example of choice set.1 6
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935V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 3 3 – 9 3 9on the patient group was undertaken by well-trained interviewers
through face-to-face interviews. They briefly described the con-
tents of the survey and if respondents had any questions, they
answered in detail as presented in the questionnaire. For the
health care professional group, the questionnaires filled out by
nurses and pharmacists working in sevenmajor hospitals in Seoul
were collected. Medical oncologists were individually contacted,
and questionnaires were sent out and returned via e-mail.
The survey was conducted between September and October
2010; 200 persons in the patient group (i.e., 140 cancer patients and
60 patients’ family members) and 285 persons in the health care
professional group (i.e., 39 medical oncologists, 34 oncology
nurses, 133 general nurses, and 79 pharmacists) completed the
survey (response rate for medical oncologists: 61.9% [39 of 63],
nurses: 98.2% [167 of 170], and pharmacists: 84.9% [79 of 93]). Data
from 444 of the total of 485 respondents—except 41 irrational re-
spondents (20 patients, 8 patients’ family members, 1 oncology
nurse, 11 general nurses, and 1 pharmacist)—were analyzed, in-
cluding 172 persons in the patient group, 39 doctors, 33 oncology
nurses, 122 general nurses, and 78 pharmacists (Table 2). Irrational
respondents were defined as those who chose an inferior scenario
in the irrationality check questionnaire.
Analyses
This study employed the conditional logit regressionmodel to an-
alyze the impacts of attribute and level on drug preference by
using STATA version 10.1.
Coefficients derived from the conditional logit model can be
expressed as the following equation:
V  1PFS  2BMS  3HFSR  4GI perforation  5Bleeding
 6Administration
here V is the utility derived for targeted therapy and 1 to 6 are
the coefficients of each attribute.
The coefficients and their confidence intervals of each attribute
are specified in Table 3. If the coefficient estimated from the con-
ditional logit regression model is statistically significant, its attri-
bute holds significance in drug preference, with the sign of the
coefficient representing either a positive effect or a negative effect
on drug choice and the magnitude of the coefficient representing
the relative importance [20]. As each attribute has a different
Table 2 – Characteristics of respondents.
Characteristics % (persons)
Total
respondents
Analysis
included
Patient group
Composition
Cancer patient 70 (140) 69.8 (120)
Patients’ family member 30 (60) 30.2 (52)
Sex
Male 36.5 (73) 34.3 (59)
Female 63.5 (127) 65.7 (113)
Age (y)
Cancer patient 57.3 57.2
Patients’ family member 47.1 47.1
Health care professional
group
Doctor (medical
oncologist)
13.7 (39) 14.3 (39)
Oncology nurse 11.9 (34) 12.1 (33)
General nurse 46.7 (133) 44.9 (122)
Pharmacist 27.7 (79) 28.7 (78)range of levels, the coefficient ismultiplied by the difference of theT C P B H G B A N * †
936 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 3 3 – 9 3 9levels to ensure the sum amounts to 100%; the ratio of each attri-
bute, meaning the relative importance, was then calculated to de-
rive the attribute’s relative contribution to preference (Fig. 2) [15].
The odds ratios (ORs) for the attribute demonstrate the effect
on the likelihood of expressing preference for a treatment in case
of the probability of experiencing the attribute increasing by one
unit.
Expressed as the ratio of coefficients between two attributes,
themarginal rate of substitution refers to the extent of willingness
to trade-off one attribute for another [14]. We divided the coeffi-
cient of PFS by each coefficient of other attributes to determine the
acceptability of adverse events if the PFS were extended by 1
month. Subgroup analyses were carried out to compare the differ-
ences in preferences between the patient group and the health
care professional groups by using the Chow test, which can be
used to explore whether the coefficients estimated over one group
of data are equal to the coefficients estimated over another.
Results
DCE results
The coefficients of each attribute were statistically significant in
both the patient group and the health care professional group,
indicating that all six attributes are important for drug preference
(Table 3).While the sign of the coefficient for PFSwas positive, that
for adverse events and administration was negative. Therefore,
the preferences increased with greater drug efficacy and de-
creased when adverse events occurred more frequently or the ad-
ministration method was switched from oral to injection. In the
patient group, when the PFS was prolonged by 1 month and the
other attributes remained unchanged, preference increased by
12.2% (OR 1.122) compared with 36.7% (OR 1.367) for the health
care professional group (Table 3). When the administration
method was switched from oral to injection, preferences were
lowered by 45.1% (OR 0.549) for the patient group and by 66.2% (OR
0.338) for the health care professional group. The coefficients for
PFS, HFSR, and GI perforation and administration differed signifi-
cantly between the patient group and the health care professional
7% 
31% 
23% 
13% 
31% 
18% 
9% 
5%
12% 
29% 
12% 1
12% 
36% 
12% 
22% 
32% 
15% 
0% 
5% 
10% 
15% 
20% 
25% 
30% 
35% 
PFS BMS HFSR GI pe
Fig. 2 – Relative importance of attributes by group. BMS, bon
skin reaction; PFS, progression-free survival.group.Subgroup analyses
The coefficients also showed the same pattern in subgroup anal-
yses (Table 4). The coefficients of the patients and patients’ family
members were not statistically different and therefore we did not
separate them into two groups. The patient group and doctors
demonstrated significant differences in PFS, HFSR, and adminis-
tration. Significant differences were found in the coefficients of
other attributes besides PFS and bleeding between the patient
group and nurses. Significant differences were also found in PFS
and BMS between the patient group and pharmacists. Differences
were even found within the health care professional groups, with
doctors and nurses differing on PFS and BMS and doctors and
pharmacists showing differences on BMS and administration.
In the comparison of ranking the adverse events, where re-
spondents were asked to rank events by order of severity, doctors
and nurses replied that GI perforation was the most serious ad-
verse event while the patient group and pharmacists thought that
BMS was the most serious (Table 5).
Relative importance
The relative contribution of each attribute to preference is dis-
played in Figure 2. The relative contribution of PFS was 31% for
doctors, while it was 7% for the patient group, 22% for pharma-
cists, and 12% for nurses, showing considerable gaps across sub-
groups. The second most important attribute for doctors was the
administration method, while adverse events contributed less to
preference. Nurses, pharmacists, and the patient group replied
that the relative importance of BMS was the greatest.
Marginal rate of substitution between attributes
If the PFS were prolonged by 1 month, doctors would be willing to
accept 9.6% of BMS and 11.8% of HFSR. The values were 3.9% and
4.8%, respectively, for pharmacists, while the numbers were
slightly smaller for nurses. For the patient group, the acceptable
percentages of these two adverse events were 1.3% and 1.0%, re-
13% 13% 
14% 
22% 
14% 
24% 
 
14% 
22% 
6% 
11% 
14% 
tion Bleeding Administration 
patient group 
medical oncologist 
oncology nurse 
general nurse 
pharmacist 
rrow suppression; GI, gastrointestinal; HFSR, hand-foot 
0% 
4%
rfora
e maspectively (Table 6).
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This study shows that preferences in relation to efficacy, adverse
events, and administration method for targeted agents of mRCC
were significantly different between the patient group and the
health care professional group. Both groups took into account not
only efficacy but also adverse events and the administration
method in considering preferences, but their relative contribution
to preference varied substantially by groups.
The health care professional group placed relatively greater
value on efficacy and oral administration in comparison with the
patient group. Patients considered adverse events to be more im-
portant regarding their preference, and consequently favored
drugs with less adverse events, regardless of the types and sever-
ity of adverse events. Similar to the findings of our study, patients
with a cardiovascular condition showed more averse attitudes to
drug treatment than did health professionals and they were more
distressed about side effects [27].
To recognize the trade-offs between two attributes, the mar-
ginal rate of substitution was identified. While the patients
were willing to trade-off 1-month prolongation of PFS with low
levels of all adverse events, doctors who placed the greatest
value on efficacy were willing to accept more adverse events
than patients. Doctors’ preferences increased more compared
with other groups in the event that the efficacy could be im-
proved or if the administration method were changed from in-
jection to oral administration.
There aremany factors involved in explaining the difference in
the preferences between the patient group and the health care
professional group such as drug taker’s perspective, health belief,
and sociocultural background [28]. One of the causes of the differ-
ence in the preferences shown in this studymay be the disparity of
the expectations for treatment and adverse events. It appears that
the patient group possesses relatively less information on dis-
eases anddrugs comparedwith health care professionals and they
might not fully understand the medical information given [29]
such as various adverse events and their severity. If a drug’s effi-
cacy does not turn out to be as great as expected or if patients
experience severe or frequently occurring adverse events unex-
pectedly, they might not continue their treatment [9] and conse-
quently the treatment outcome would be affected negatively [10].
Doctors frequently are not aware of patients’ misunderstanding
regarding treatment and treatment outcome [30].
On the contrary, the health care professional group, especially
medical oncologists, possesses detailed information and abun-
dant clinical experience on diseases and therapies; however, they
do not adequately know the patients’ preference [31]. They might
not be sufficiently aware of patient suffering caused by adverse
events and the impact of drugs on patients’ quality of life. Under
such circumstances, they would choose drugs whose efficacy is
improved, even slightly, despite adverse events, if there are no
alternative treatments; they would also choose drugs if the ad-
verse events could be prevented or controlled easily, even if they
are more severe or frequent.
Doctors and nurses considered the administrationmethod im-
portantly in preference and, interestingly, they preferred orally
administered drugs, whereas the patient group showed lower
preference. It appears that the patients were accustomed to vis-
iting the hospital regularly in line with schedules for treatment
and, to some extent, might look forward to seeing their doctors
more often in the case of severe diseases. Fallowfield et al. [32]
reported that 63% of the patients with advanced breast cancer
preferred orally administered drugs but about one fourth of the
patients preferred monthly injection because of convenience
and adherence. The patients’ preference for administration
changed if they possessed information of the efficacy or adverse
events of the drug [32].
T C Pr B H G B A * †
938 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 3 3 – 9 3 9A previous study [33] reported that patients worried about a
higher rate of adverse events more than severity, and experience
of adverse events did not markedly influence their judgment. In
other studies [34,35], doctors and patients represented different
preferences and trade-offs for efficacy and adverse events. We
also observed in this study that a higher rate of adverse events
might have a negative impact on the patients’ preference. Previ-
ous studies comparing preferences between patients and physi-
cians for preventive osteoporosis drug treatment have also shown
that preferences differ between patients and physicians. General
practitioners placed higher relative values on the effectiveness of
preventive osteoporosis drug treatment and shorter treatment du-
ration, respectively, than did patients [19].We also identified a gap
in preferences between experts and patients and furthermore
among health care professional groups.
The patients’ opinion is growing more important in treatment
decisions [36], with the growing trend of patient-centered decision
making [37], andmost cancer patients would like to be involved in
the decision-making process [31,38]. There is a wide disagree-
ment, however, between physicians and patients [39], and it was
reported that half of the patients took a passive decision-making
role [40]. Cancer patients continue to have unmet communication
needs associated with treatment-related information [41]. A pre-
vious study found that communication between doctors and pa-
tients and providing more information to patients would be help-
ful in decisionmaking [34] and giving access to accurate, balanced,
evidence-based, and comprehensive information about health
care options contributed in improving patients’ adherence to
treatment [42]. That is, ensuring that patients have a better under-
standing of their situation and giving information to patients
through good communication would help in decision making and
eventually improve the treatment outcome [43–45]. Therefore, ef-
forts such as effective communication with easily understandable
information about the risks and expected outcomes and operation
of a patient education program are needed to reduce the differ-
Table 5 – Proportion of responses evaluating each adverse
Adverse events (%) Patient group
(n  172)
Doctors
(n  39)
Bone marrow suppression 41 10
Hand-foot skin reaction 19 0
Gastrointestinal perforation 22 77
Bleeding 18 13
Total 100 100
Table 6 – Marginal rate of substitution.
Marginal rate of
substitution
Meaning
1/2 Bone marrow suppression that can be
accepted if the PFS increases by
1 mo (%P)
1/3 Hand-foot skin reaction that can be
accepted if the PFS increases by
1 mo (%P)
1/4 Gastrointestinal perforation that can
be accepted if the PFS increases by
1 mo (%P)
1/5 Bleeding that can be accepted if the
PFS increases by 1 mo (%P)
1/6 Administration that can be accepted if
the PFS increases by 1 mo (oral  0,
injection  1)ence in preferences between patients and experts. In addition,
differences in preferences among health care professional groups
should be addressed for harmonious treatment.
This study has several limitations.We selected PFS instead of OS
as an efficacy attribute, because the OS is not sufficient to represent
the pure efficacy by confounding for ethical reasons in clinical trials.
PFS is expressed in a shorter period of time than OS, and therefore
patients may feel that the efficacy of a drug is too small to be recog-
nized as being important; even a small improvement became an im-
portant target for drug development, because it is related to the end
of life of patients. On the other hand, doctors and pharmacists un-
derstood the meaning of PFS, and consequently their perceived rel-
ative importance of PFS was large in this study.
We did not confine the cancer types, and as such patients with
any cancer type could answer the questionnaire. This article focuses
on the attributes of targeted agents used in treating mRCC, whose
incidence rate is very low, and thereforewe anticipated that itwould
be impossible toenroll anadequatenumberof cases fromthis typeof
cancer patients only to derivemeaningful results. Moreover, the tar-
geted agents evaluated here are also used for treating other cancer
types, andasa result somepatientsparticipating inour surveymight
have experience andmight be familiar with the targeted agents. The
adverse events and administration used in this article may be com-
monly presented regardless of the type of cancer, but the possibility
cannot be ruled out that the efficacy attributes, which are observed
for a relatively short period of time in mRCC, may have influenced
the responses of patients with other types of cancer. Therefore, the
DCE results might be influenced by this heterogeneity of patients
with different cancer types.
In addition, the number of medical oncologists included in the
analysis was relatively small. Nevertheless, coefficients of attributes
fordoctorswere statistically significant andhencewecould compare
the preference of each group. Even though doctors are the most ap-
propriate experts in deciding treatment strategy, other clinical ex-
perts such as nurses and pharmacists also play a role in the treat-
t as the most severe.
Oncology nurses
(n  33)
General nurses
(n  122)
Pharmacists
(n  78)
18 38 59
0 4 5
58 39 32
24 19 4
100 100 100
nt
p
Doctors Nurses Pharmacists
Oncology General
9.6 2.3 1.8 3.9
11.8 3.2 3.3 4.8
3.8 0.8 1.9 2.6
3.0 1.1 1.1 2.6
0.5 0.2 0.2 0.5evenPatie
grou
1.3
1.0
0.4
0.7
0.2
0[
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939V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 3 3 – 9 3 9ment of patients, including patient care, providing instructions for
taking medicine, and management of adverse events. Hence, their
preferencemay influence the patients’ attitude, and it is thusmean-
ingful to derive the preferences of various health care professional
groups and compare the gaps among them. In this regard, it will be
an interesting further research agenda to investigate the influential
effect health care professionals and patients’ family members have
on the patient’s drug decision.
Finally, because we conducted the survey on preferences with
Korean respondents, these results can be interpreted meaning-
fully only inside Korea, although they can be applied later to other
countries with further similar studies in different settings.
In conclusion, preferences for targeted agents used in mRCC
and attributes affecting the preferences differ significantly by
groupwith respect to efficacy, adverse events, and administration
methods. The differences in the acceptable levels of adverse
events are quite different as well. Doctors prefer effective and
orally administered drugs while patients show reluctant attitudes
toward adverse events. The preference gap between the health
care professionals and the cancer patients needs to be reduced for
the successful treatment of mRCC.
Source of financial support: Pfizer Korea funded this study.
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